(Q27851775)

2

0 references

Meiling Hu

3

0 references

Aidi Tao

4

0 references

Hangbo Zhou

5

0 references

Xiaojun Zhou

6

0 references

Yujie Sun

https://scigraph.springernature.com/pub.10.1007/s12032-012-0239-3

7

0 references

publication date

December 2012

0 references

1 reference

29

0 references

page(s)

3207-15

0 references

issue

5

0 references

exact match

0 references

cites work

Young age: an independent risk factor for disease-free survival in women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Prognostic molecular markers in early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Taxane analogues against breast cancer: a quantitative structure-activity relationship study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Paclitaxel maintenance chemotherapy following intraperitoneal chemotherapy for ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Phase I study of induction chemotherapy and concomitant chemoradiotherapy with irinotecan, carboplatin, and paclitaxel for stage III non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Long-term outcomes with concurrent carboplatin, paclitaxel and radiation therapy for locally advanced, inoperable head and neck cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

A systematic overview of chemotherapy effects in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Mechanism of action of antitumor drugs that interact with microtubules and tubulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Microtubule-targeting drugs induce Bcl-2 phosphorylation and association with Pin1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Tissue inhibitor of metalloproteinases-1 in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Tissue inhibitor of metalloproteinase 1 activates normal human granulocytes, protects them from apoptosis, and blocks their transmigration during inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

TIMP-1 inhibits apoptosis in breast carcinoma cells via a pathway involving pertussis toxin-sensitive G protein and c-Src

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Tissue inhibitor of metalloproteinases-1 signalling pathway leading to erythroid cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase/phosphatidylinositol 3-kinase and MAPK signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

TIMP-1 as a tumor marker in breast cancer--an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Tissue inhibitor of metalloproteinase-1 protects MCF-7 breast cancer cells from paclitaxel-induced apoptosis by decreasing the stability of cyclin B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Adjuvant docetaxel for node-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-012-0239-3

Taxanes, microtubules and chemoresistant breast cancer.

21 January 2018

1 reference

12 December 2020

Enhanced mRNA expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in breast carcinomas is correlated with adverse prognosis

1 reference

12 December 2020

Single-agent paclitaxel for the treatment of breast cancer: an overview.

1 reference

12 December 2020

Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells

1 reference

12 December 2020

Apaf-1 and caspase-9 deficiency prevents apoptosis in a Bax-controlled pathway and promotes clonogenic survival during paclitaxel treatment

1 reference

12 December 2020

Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples

1 reference

12 December 2020

Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer

1 reference

12 December 2020